These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33994440)

  • 1. Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C.
    Sato S; Tsuzura H; Kita Y; Ikeda Y; Kabemura D; Sato S; Amano N; Yatagai N; Murata A; Shimada Y; Genda T
    Intern Med; 2021 Nov; 60(22):3569-3572. PubMed ID: 33994440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
    Fabbri G; Mastrorosa I; Vergori A; Mazzotta V; Pinnetti C; Grisetti S; Zaccarelli M; Ammassari A; Antinori A
    BMC Infect Dis; 2017 Mar; 17(1):182. PubMed ID: 28249574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Hayashi T; Ura K
    Liver Int; 2018 Jan; 38(1):76-83. PubMed ID: 28618152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection.
    Odolini S; Lanza P; Angiola A; Zaltron S; Urbinati L; Vavassori A; Nasta P; Festa E; Gargiulo F; Rodella A; Caruso A; Casari S; Castelli F; Viganò M
    New Microbiol; 2017 Jul; 40(3):218-220. PubMed ID: 28513813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review.
    Miyasaka A; Yoshida Y; Suzuki A; Masuda T; Okamoto H; Takikawa Y
    Medicine (Baltimore); 2020 Oct; 99(41):e22650. PubMed ID: 33031326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
    Nagaty A; Helmy SH; Abd El-Wahab EW
    Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment.
    Liu CJ; Sheen IS; Chen CY; Chuang WL; Wang HY; Tseng KC; Chang TT; Yang J; Massetto B; Suri V; Camus G; Jiang D; Zhang F; Gaggar A; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
    Clin Infect Dis; 2022 Aug; 75(3):453-459. PubMed ID: 34864948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
    Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
    Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses.
    Yeh ML; Hung CH; Huang JF; Liu CJ; Lee CM; Dai CY; Wang JH; Lin ZY; Lu SN; Hu TH; Yu ML; Kao JH; Chuang WL; Chen PJ; Chen DS
    PLoS One; 2011; 6(6):e20752. PubMed ID: 21695152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBV reactivation during direct-acting antiviral therapy in hepatitis B and C coinfected patients undergoing haemodialysis.
    Wang J; Hu C; Chen Y; Liu Z; Yu Q; Yang S; Dong J; Yang Y; Wu Y; Ren D; Yao N; Guo D; Tian Z; Zhao Y; Chen T; He Y; Liu J
    Antivir Ther; 2019; 24(2):77-84. PubMed ID: 30833515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.
    Kawagishi N; Suda G; Sakamori R; Matsui T; Onozawa M; Yang Z; Yoshida S; Ohara M; Kimura M; Kubo A; Maehara O; Fu Q; Hosoda S; Tokuchi Y; Suzuki K; Nakai M; Sho T; Morikawa K; Natsuizaka M; Ogawa K; Sakai H; Ohnishi S; Baba M; Takehara T; Sakamoto N
    Sci Rep; 2022 Oct; 12(1):16800. PubMed ID: 36207368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
    Tamori A; Abiru S; Enomoto H; Kioka K; Korenaga M; Tani J; Enomoto M; Sugiyama M; Masaki T; Kawada N; Yatsuhashi H; Nishiguchi S; Mizokami M
    J Viral Hepat; 2018 May; 25(5):608-611. PubMed ID: 29194858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
    Spaan M; Bruce M; Agarwal K; Carey I
    Antivir Ther; 2018; 23(6):539-542. PubMed ID: 30309997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Yu ML; Lee CM; Chuang WL; Lu SN; Dai CY; Huang JF; Lin ZY; Hu TH; Chen CH; Hung CH; Wang JH; Chen CL; Kao JH; Lai MY; Liu CH; Su TH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Chen PJ; Liu CJ; Chen DS
    J Infect Dis; 2010 Jul; 202(1):86-92. PubMed ID: 20482252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B reactivation and outcomes in persons treated with directly acting antiviral agents against hepatitis C virus: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Abou-Samra AB
    Aliment Pharmacol Ther; 2018 Feb; 47(3):412-420. PubMed ID: 29181838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Yanny BT; Latt NL; Saab S; Han S; Choi G; Kramer J; Sahota AK
    J Clin Gastroenterol; 2018; 52(10):908-912. PubMed ID: 29334502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir.
    Collins JM; Raphael KL; Terry C; Cartwright EJ; Pillai A; Anania FA; Farley MM
    Clin Infect Dis; 2015 Oct; 61(8):1304-6. PubMed ID: 26082511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.